Flibanserin

Flibanserin Update: Health and Safety Concerns Continue to Be Profound

By NWHN Staff | Mar 2, 2016 | Comments Off on Flibanserin Update: Health and Safety Concerns Continue to Be Profound

Rather than a failed “fix-all” pill, NWHN encourages rigorous research be conducted exploring the causes of women’s sexual problems, possible solutions, and what, if anything, might constitute “normal” when it comes to women’s sexuality.

Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New Campaign

By NWHN Staff | Nov 18, 2015 | Comments Off on Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New Campaign

FOR IMMEDIATE RELEASE

Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043

New Campaign Warns Women of Harm from Drug FDA Approved in August

By Cindy Pearson | Nov 17, 2015 | Comments Off on New Campaign Warns Women of Harm from Drug FDA Approved in August

FOR IMMEDIATE RELEASE
To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994

Pass on the Pink Pill – Or Pass Out!

By NWHN Staff | Nov 15, 2015 | Comments Off on Pass on the Pink Pill – Or Pass Out!

The NWHN is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido.

Warning of Marginal Benefits and Serious Side Effects as Drug Sales Begin

By Cindy Pearson | Nov 12, 2015 | Comments Off on Warning of Marginal Benefits and Serious Side Effects as Drug Sales Begin

FOR IMMEDIATE RELEASE

To schedule an interview with Cindy Pearson and Susan Wood, contact Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994

Consumer Alert — Pass on the Pink Pill or Pass Out

By NWHN Staff | Nov 12, 2015 | Comments Off on Consumer Alert — Pass on the Pink Pill or Pass Out

The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.

Flibanserin: The FDA’s Approval Is Bad Science and a Bad Precedent

By NWHN Staff | Nov 10, 2015 | Comments Off on Flibanserin: The FDA’s Approval Is Bad Science and a Bad Precedent

This year, the Food and Drug Administration (FDA) made history — for all the wrong reasons.

The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

By NWHN Staff | Oct 16, 2015 | Comments Off on The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640

Top 10 Things to Know About Today’s Sex Drive Drugs

By NWHN Staff | Oct 15, 2015 | Comments Off on Top 10 Things to Know About Today’s Sex Drive Drugs

Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.

Flibanserin Approved… Women’s Health and Safety Ignored!

By Shaniqua Seth | Aug 19, 2015 | Comments Off on Flibanserin Approved… Women’s Health and Safety Ignored!

I’m disappointed and you should be too. Today, the Food & Drug Administration announced the approval of flibanserin, a proposed treatment for “hypoactive sexual desire disorder” in women. Since its founding, the National Women’s Health Network has ensured that the voices of women consumers are heard and respected. Today, clever marketing trumped decades worth of consumer protections that the Network has worked hard to secure and maintain.